<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20190801062500Z</creation_date><modification_date>D:20191029154400Z</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-1-19-1392_h_dec_0.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 11.11.2019c(2019)8131 (final)</p></section><section><header>commission implementing decisionof 11.11.2019
 granting a conditional marketing authorisation under regulation (ec) no 726/2004 of the 
 european parliament and of the council for &quot;ervebo - ebola zaire vaccine (rvsv∆g-
 zebov-gp, live)&quot;, a medicinal product for human use</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 11.11.2019
 granting a conditional marketing authorisation under regulation (ec) no 726/2004 of 
 the european parliament and of the council for &quot;ervebo - ebola zaire vaccine 
 (rvsv∆g-zebov-gp, live)&quot;, a medicinal product for human use</header><p>(text with eea relevance)(only the dutch text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1, and in particular article 10(2) and 14-a thereof,having regard to commission regulation (ec) no 507/2006 on the conditional marketing 
 authorisation for medicinal products for human use falling within the scope of regulation 
 (ec) no 726/2004 of the european parliament and of the council
 2,having regard to the application submitted by merck sharp &amp; dohme b.v., on 28 march 
 2019, under article 4(1) of regulation (ec) no 726/2004,
 having regard to the opinion of the european medicines agency, formulated on 17 october 
 2019 by the committee for medicinal products for human use,
 whereas:
 (1)
 the medicinal product &quot;ervebo - ebola zaire vaccine (rvsv∆g-zebov-gp, live)&quot; 
 complies with the requirements set out in directive 2001/83/ec of the european 
 parliament and of the council of 6 november 2001 on the community code relating 
 to medicinal products for human use
 3.(2)
 &quot;ervebo - ebola zaire vaccine (rvsv∆g-zebov-gp, live)&quot; falls within the scope of 
 regulation (ec) no 507/2006, in particular article 2(1). in addition, as set out in 
 annex iv, the medicinal product meets the requirements of article 4 of this 
 regulation for the granting of a conditional marketing authorisation.
 (3)
 authorisation for the placing on the market of &quot;ervebo - ebola zaire vaccine 
 (rvsv∆g-zebov-gp, live)&quot; should therefore be granted subject to certain 
 requirements, in accordance with article 14-a of regulation (ec) no 726/2004 and 
 regulation (ec) no 507/2006.
 1oj l 136, 30.4.2004, p. 1.2oj l 92, 30.3.2006, p. 6.3oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>(4)the committee for medicinal products for human use considered that &quot;rvsv∆g-
 zebov-gp (recombinant vesicular stomatitis virus strain indiana with a deletion of 
 the vsv envelope glycoprotein replaced with the zaire ebola virus kikwit 1995 
 strain surface glycoprotein)&quot; is a new active substance.
 (5)
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use,
 has adopted this decision:
 article 1the conditional marketing authorisation provided for in article 3 and 14-a of regulation (ec) no 726/2004 is granted for the medicinal product &quot;ervebo - ebola zaire vaccine 
 (rvsv∆g-zebov-gp, live)&quot;, the characteristics of which are summarised in annex i to this 
 decision. &quot;ervebo - ebola zaire vaccine (rvsv∆g-zebov-gp, live)&quot; shall be registered in 
 the union register of medicinal products under number eu/1/19/1392.
 article 2the marketing authorisation concerning the medicinal product referred to in article 1 shall be subject to compliance with the requirements and specifications set out in annex ii, including 
 with regard to manufacturing. those requirements shall be reviewed annually.
 article 3the labelling and package leaflet concerning the medicinal product referred to in article 1 shall comply with the conditions set out in annex iii.
 article 4the period of validity of the authorisation shall be one year from the date of notification of this decision.
 article 5this decision is addressed to merck sharp &amp; dohme b.v., waarderweg 39, 2031 bn haarlem, nederland.
 done at brussels, 11.11.2019
 for the commissionanne bucher
 director-general</p></section></body></xml>